Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2011 (2011), Article ID 134679, 13 pages
http://dx.doi.org/10.4061/2011/134679
Review Article

Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines

1Division of Pediatric Clinical Research, Department of Pediatrics, University of Miami Miller School of Medicine, Medical Campus-BCRI-D820, 1580 NW 10th Avenue, 5th Floor, Miami, FL 33136, USA
2Holtz Children's Hospital of the University of Miami/Jackson Memorial Medical Center, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
3Department of Pediatrics (D820), University of Miami Miller School of Medicine, P.O. Box 016820, Miami, FL 33101, USA
4Department of Pediatrics, University of Miami, 1601 NW 12th Ave, 9th floor (D820), USA

Received 15 October 2010; Accepted 15 December 2010

Academic Editor: Jean-Bernard Durand

Copyright © 2011 Vivian I. Franco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Li, T. D. Thompson, J. W. Miller, L. A. Pollack, and S. L. Stewart, “Cancer incidence among children and adolescents in the United States, 2001–2003,” Pediatrics, vol. 121, no. 6, pp. e1470–e1477, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics,” Ca-A Cancer Journal for Clinicians, vol. 60, pp. 277–300, 2010. View at Google Scholar
  3. L. B. Silverman, K. E. Stevenson, J. E. O'Brien et al., “Long-term results of dana-farber cancer institute all consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000),” Leukemia, vol. 24, no. 2, pp. 320–334, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. B. Mariotto, J. H. Rowland, K. R. Yabroff et al., “Long-term survivors of childhood cancers in the United States,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 4, pp. 1033–1040, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. C. Oeffinger, A. C. Mertens, C. A. Sklar et al., “Chronic health conditions in adult survivors of childhood cancer,” The New England Journal of Medicine, vol. 355, no. 15, pp. 1572–1582, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. C. Mertens, Q. Liu, J. P. Neglia et al., “Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study,” Journal of the National Cancer Institute, vol. 100, no. 19, pp. 1368–1379, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. A. Mulrooney, M. W. Yeazel, T. Kawashima et al., “Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort,” British Medical Journal, vol. 339, p. b4606, 2009. View at Google Scholar · View at Scopus
  8. T. R. Möller, S. Garwicz, L. Barlow et al., “Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries,” Journal of Clinical Oncology, vol. 19, no. 13, pp. 3173–3181, 2001. View at Google Scholar · View at Scopus
  9. M. Tukenova, C. Guibout, O. Oberlin et al., “Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1308–1315, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. E. Lipshultz and M. J. Adams, “Cardiotoxicity after childhood cancer: beginning with the end in mind,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1276–1281, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. E. Lipshultz, J. A. Alvarez, and R. E. Scully, “Anthracycline associated cardiotoxicity in survivors of childhood cancer,” Heart, vol. 94, no. 4, pp. 525–533, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. C. Reulen, D. L. Winter, C. Frobisher et al., “Long-term cause-specific mortality among survivors of childhood cancer,” Journal of the American Medical Association, vol. 304, no. 2, pp. 172–179, 2010. View at Publisher · View at Google Scholar · View at PubMed
  13. G. Levitt, A. Anazodo, M. Burch, and K. Bunch, “Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need?” European Journal of Cancer, vol. 45, no. 17, pp. 3027–3034, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. E. Lipshultz, S. D. Colan, R. D. Gelber, A. R. Perez-Atayde, S. E. Sallan, and S. P. Sanders, “Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood,” The New England Journal of Medicine, vol. 324, no. 12, pp. 808–815, 1991. View at Google Scholar · View at Scopus
  15. M. J. Adams and S. E. Lipshultz, “Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention,” Pediatric Blood and Cancer, vol. 44, no. 7, pp. 600–606, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. A. Giantris, L. Abdurrahman, A. Hinkle, B. Asselin, and S. E. Lipshultz, “Anthracycline-induced cardiotoxicity in children and young adults,” Critical Reviews in Oncology/Hematology, vol. 27, no. 1, pp. 53–68, 1998. View at Publisher · View at Google Scholar
  17. M. A. Grenier and S. E. Lipshultz, “Epidemiology of anthracycline cardiotoxicity in children and adults,” Seminars in Oncology, vol. 25, no. 4, pp. 72–85, 1998. View at Google Scholar
  18. E. Barry, J. A. Alvarez, R. E. Scully, T. L. Miller, and S. E. Lipshultz, “Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management,” Expert Opinion on Pharmacotherapy, vol. 8, no. 8, pp. 1039–1058, 2007. View at Publisher · View at Google Scholar · View at PubMed
  19. K. Nysom, K. Holm, S. R. Lipsitz et al., “Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 545–550, 1998. View at Google Scholar
  20. M. S. Horenstein, R. S. Vander Heide, and T. J. L'Ecuyer, “Molecular basis of anthracycline-induced cardiotoxicity and its prevention,” Molecular Genetics and Metabolism, vol. 71, no. 1-2, pp. 436–444, 2000. View at Publisher · View at Google Scholar · View at PubMed
  21. D. Lebrecht, B. Setzer, U. P. Ketelsen, J. Haberstroh, and U. A. Walker, “Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy,” Circulation, vol. 108, no. 19, pp. 2423–2429, 2003. View at Publisher · View at Google Scholar · View at PubMed
  22. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer, “Anthracycline cardiotoxicity: from bench to bedside,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3777–3784, 2008. View at Publisher · View at Google Scholar · View at PubMed
  24. T. Šimůnek, M. Štěrba, O. Popelová, M. Adamcová, R. Hrdina, and V. Gerši, “Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron,” Pharmacological Reports, vol. 61, no. 1, pp. 154–171, 2009. View at Google Scholar
  25. K. Nicolay, R. van der Neut, J. J. Fok, and B. de Kruijff, “Effects of adriamycin on lipid polymorphism in cardiolipin-containing model and mitochondrial membranes,” Biochimica et Biophysica Acta, vol. 819, no. 1, pp. 55–65, 1985. View at Publisher · View at Google Scholar
  26. R. C. F. Leonard, S. Williams, A. Tulpule, A. M. Levine, and S. Oliveros, “Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet),” Breast, vol. 18, no. 4, pp. 218–224, 2009. View at Publisher · View at Google Scholar · View at PubMed
  27. N. Ashley and J. Poulton, “Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs,” Biochemical and Biophysical Research Communications, vol. 378, no. 3, pp. 450–455, 2009. View at Publisher · View at Google Scholar · View at PubMed
  28. K. B. Wallace, “Doxorubicin-induced cardiac mitochondrionopathy,” Pharmacology and Toxicology, vol. 93, no. 3, pp. 105–115, 2003. View at Publisher · View at Google Scholar
  29. K. L. Thompson, B. A. Rosenzweig, J. Zhang et al., “Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 303–314, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. J. H. Doroshow, G. Y. Locker, and C. E. Myers, “Enzymatic defenses of the mouse heart against reactive oxygen metabolites. Alterations produced by doxorubicin,” Journal of Clinical Investigation, vol. 65, no. 1, pp. 128–135, 1980. View at Google Scholar
  31. H. Ito, S. C. Miller, M. E. Billingham et al., “Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 11, pp. 4275–4279, 1990. View at Publisher · View at Google Scholar
  32. X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer, “The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine,” Molecular Interventions, vol. 5, no. 3, pp. 163–171, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. B. Chen, X. Peng, L. Pentassuglia, C. C. Lim, and D. B. Sawyer, “Molecular and cellular mechanisms of anthracycline cardiotoxicity,” Cardiovascular Toxicology, vol. 7, no. 2, pp. 114–121, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. A. De Angelis, E. Piegari, D. Cappetta et al., “Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function,” Circulation, vol. 121, no. 2, pp. 276–292, 2010. View at Publisher · View at Google Scholar · View at PubMed
  35. B. Kalyanaraman, J. Joseph, S. Kalivendi, S. Wang, E. Konorev, and S. Kotamraju, “Doxorubicin-induced apoptosis: implications in cardiotoxicity,” Molecular and Cellular Biochemistry, vol. 234-235, pp. 119–124, 2002. View at Publisher · View at Google Scholar
  36. R. Jurcut, H. Wildiers, J. Ganame, J. D'hooge, R. Paridaens, and J. U. Voigt, “Detection and monitoring of cardiotoxicity—what does modern cardiology offer?” Supportive Care in Cancer, vol. 16, no. 5, pp. 437–445, 2008. View at Publisher · View at Google Scholar · View at PubMed
  37. P. Rusconi, O. Gómez-Marín, M. Rossique-González et al., “Carvedilol in children with cardiomyopathy: 3-Year experience at a single institution,” Journal of Heart and Lung Transplantation, vol. 23, no. 7, pp. 832–838, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. S. Lowis, I. Lewis, A. Elsworth et al., “A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours,” British Journal of Cancer, vol. 95, no. 5, pp. 571–580, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. D. Lebrecht, A. Kokkori, U. P. Ketelsen, B. Setzer, and U. A. Walker, “Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin,” Journal of Pathology, vol. 207, no. 4, pp. 436–444, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. M. Ryberg, D. Nielsen, G. Cortese, G. Nielsen, T. Skovsgaard, and P. K. Andersen, “New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients,” Journal of the National Cancer Institute, vol. 100, no. 15, pp. 1058–1067, 2008. View at Publisher · View at Google Scholar · View at PubMed
  41. M. Tokarska-Schlattner, M. Zaugg, C. Zuppinger, T. Wallimann, and U. Schlattner, “New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics,” Journal of Molecular and Cellular Cardiology, vol. 41, no. 3, pp. 389–405, 2006. View at Publisher · View at Google Scholar · View at PubMed
  42. S. E. Lipshultz, R. E. Scully, and H. M. Smith, “Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia,” in Proceedings of the 5th World Congress of Paediatric Cardiology and Cardiac Surgery (PCCS '09), Cairns, Australia, June 2009, Cardiomyopathy Poster Session. PCCS2009 Program page 133.
  43. D. D. Von Hoff, M. Rozencweig, and M. Layard, “Daunomycin induced cardiotoxicity in children and adults. A review of 110 cases,” American Journal of Medicine, vol. 62, no. 2, pp. 200–208, 1977. View at Google Scholar
  44. S. E. Lipshultz, S. R. Lipsitz, T. L. Miller et al., “Late cardiac status in long-term survivors of childhood high-risk all 8 years after continuous or bolus infusion of doxorubicin: the DFCI Childhood ALL 91-01 Randomized Trial,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, p. 9513, 2010. View at Google Scholar
  45. S. E. Lipshultz, N. Rifai, S. E. Sallan et al., “Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury,” Circulation, vol. 96, no. 8, pp. 2641–2648, 1997. View at Google Scholar
  46. L. Wang and R. Weinshilboum, “Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions,” Oncogene, vol. 25, no. 11, pp. 1629–1638, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. S. Deng and L. Wojnowski, “Genotyping the risk of anthracycline-induced cardiotoxicity,” Cardiovascular Toxicology, vol. 7, no. 2, pp. 129–134, 2007. View at Publisher · View at Google Scholar · View at PubMed
  48. J. G. Blanco, W. M. Leisenring, V. M. Gonzalez-Covarrubias et al., “Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQ01 in patients who developed anthracycline-related congestive heart failure after childhood cancer,” Cancer, vol. 112, no. 12, pp. 2789–2795, 2008. View at Publisher · View at Google Scholar · View at PubMed
  49. C. J. Miranda, H. Makui, R. J. Soares et al., “Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin,” Blood, vol. 102, no. 7, pp. 2574–2580, 2003. View at Publisher · View at Google Scholar · View at PubMed
  50. J. P. Krischer, S. Epstein, D. D. Cuthbertson, A. M. Goorin, M. L. Epstein, and S. E. Lipshultz, “Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience,” Journal of Clinical Oncology, vol. 15, no. 4, pp. 1544–1552, 1997. View at Google Scholar
  51. J. P. Krischer, D. D. Cuthbertson, S. Epstein, A. M. Goorin, M. L. Epstein, and S. E. Lipshultz, “Risk factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience,” Progress in Pediatric Cardiology, vol. 8, no. 2, pp. 83–90, 1997. View at Publisher · View at Google Scholar
  52. “Establishing and enhancing services for childhood cancer survivors: long-term follow-up program resource guide,” Children’s Oncology Group, 2007, http://www.survivorshipguidelines.org/.
  53. S. E. Lipshultz, R. E. Scully, S. R. Lipsitz et al., “Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial,” The Lancet Oncology, vol. 11, no. 10, pp. 950–961, 2010. View at Publisher · View at Google Scholar
  54. D. Cardinale, M. T. Sandri, A. Colombo et al., “Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy,” Circulation, vol. 109, no. 22, pp. 2749–2754, 2004. View at Publisher · View at Google Scholar · View at PubMed
  55. D. Cardinale, M. T. Sandri, A. Martinoni et al., “Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy,” Journal of the American College of Cardiology, vol. 36, no. 2, pp. 517–522, 2000. View at Publisher · View at Google Scholar
  56. S. E. Lipshultz, J. C. L. Wong, S. R. Lipsitz et al., “Frequency of clinically unsuspected myocardial injury at a children's hospital,” American Heart Journal, vol. 151, no. 4, pp. 916–922, 2006. View at Publisher · View at Google Scholar · View at PubMed
  57. E. H. Herman, J. Zhang, S. E. Lipshultz et al., “Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2237–2243, 1999. View at Google Scholar
  58. S. E. Lipshultz, N. Rifai, V. M. Dalton et al., “The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia,” The New England Journal of Medicine, vol. 351, no. 2, pp. 145–153, 2004. View at Publisher · View at Google Scholar · View at PubMed
  59. S. E. Lipshultz, T. L. Miller, and R. E. Scully, “Diagnostic value of cardiac troponin T, N-terminal pro-brain natriuretic peptide, and high-sensitivity C-reactive protein during Doxorubicin therapy in children with acute lymphoblastic 6 leukemia,” Circulation, vol. 122, no. 21, supplement, A20432, 2010. View at Google Scholar
  60. A. Martinez-Rumayor, A. M. Richards, J. C. Burnett, and J. L. Januzzi, “Biology of the natriuretic peptides,” American Journal of Cardiology, vol. 101, no. 3, pp. S3–S8, 2008. View at Publisher · View at Google Scholar · View at PubMed
  61. T. J. Wang, M. G. Larson, D. Levy et al., “Plasma natriuretic peptide levels and the risk of cardiovascular events and death,” The New England Journal of Medicine, vol. 350, no. 7, pp. 655–663, 2004. View at Publisher · View at Google Scholar · View at PubMed
  62. C. Kragelund, B. Grønning, L. Køber, P. Hildebrandt, and R. Steffensen, “N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease,” The New England Journal of Medicine, vol. 352, no. 7, pp. 666–675, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. J. Grewal, R. S. McKelvie, H. Persson et al., “Usefulness of N-terminal pro–brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction,” American Journal of Cardiology, vol. 102, no. 6, pp. 733–737, 2008. View at Publisher · View at Google Scholar · View at PubMed
  64. S. Black, I. Kushner, and D. Samols, “C-reactive protein,” The Journal of Biological Chemistry, vol. 279, no. 47, pp. 48487–48490, 2004. View at Publisher · View at Google Scholar · View at PubMed
  65. C. Ratnasamy, D. D. Kinnamon, S. E. Lipshultz et al., “Associations between neurohormonal and inflammatory activation and heart failure in children,” Progress in Pediatric Cardiology, vol. 24, pp. 81–82, 2007. View at Google Scholar
  66. S. K. Singh, M. V. Suresh, B. Voleti, and A. Agrawal, “The connection between C-reactive protein and atherosclerosis,” Annals of Medicine, vol. 40, no. 2, pp. 110–120, 2008. View at Publisher · View at Google Scholar · View at PubMed
  67. S. E. Lipshultz, S. R. Lipsitz, A. S. Hinkle et al., “Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based NCI study,” Circulation, vol. 112, supplement 2, p. 476, 2005. View at Google Scholar
  68. E. Petricoin, M. M. Ross, and W. Zhou, “Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry,” Journal of Clinical Oncology, vol. 28, p. 9528, 2010. View at Google Scholar
  69. S. E. Lipshultz, S. R. Lipsitz, S. E. Sallan et al., “Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2629–2636, 2005. View at Publisher · View at Google Scholar · View at PubMed
  70. S. E. Lipshultz, S. R. Lipsitz, S. M. Mone et al., “Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer,” The New England Journal of Medicine, vol. 332, no. 26, pp. 1738–1743, 1995. View at Publisher · View at Google Scholar · View at PubMed
  71. S. E. Lipshultz and S. D. Colan, “Cardiovascular trials in long-term survivors of childhood cancer,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 769–773, 2004. View at Publisher · View at Google Scholar · View at PubMed
  72. K. Sorensen, G. A. Levitt, C. Bull, I. Dorup, and I. D. Sullivan, “Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study,” Cancer, vol. 97, no. 8, pp. 1991–1998, 2003. View at Publisher · View at Google Scholar · View at PubMed
  73. J. Ganame, P. Claus, A. Uyttebroeck et al., “Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients,” Journal of the American Society of Echocardiography, vol. 20, no. 12, pp. 1351–1358, 2007. View at Publisher · View at Google Scholar · View at PubMed
  74. K. Nysom, S. D. Colan, and S. E. Lipshultz, “Late cardiotoxicity following anthracycline therapy for childhood cancer,” Progress in Pediatric Cardiology, vol. 8, no. 3, pp. 121–138, 1998. View at Publisher · View at Google Scholar
  75. M. A. Schorin, S. Blattner, R. D. Gelber et al., “Treatment of childhood acute lymphoblastic leukemia: results of Dana- Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01,” Journal of Clinical Oncology, vol. 12, no. 4, pp. 740–747, 1994. View at Google Scholar
  76. J. M. Fulbright, W. Huh, P. Anderson, and J. Chandra, “Can anthracycline therapy for pediatric malignancies be less cardiotoxic?” Current Oncology Reports, vol. 12, no. 6, pp. 411–419, 2010. View at Publisher · View at Google Scholar · View at PubMed
  77. A. A. Gabizon, O. Lyass, G. J. Berry, and M. Wildgust, “Cardiac safety of pegylated liposomal doxorubicin (Doxil®/Caelyx®) demonstrated by endomyocardial biopsy in patients with advanced malignancies,” Cancer Investigation, vol. 22, no. 5, pp. 663–669, 2004. View at Publisher · View at Google Scholar
  78. N. M. Marina, D. Cochrane, E. Harney et al., “Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study,” Clinical Cancer Research, vol. 8, no. 2, pp. 413–418, 2002. View at Google Scholar
  79. G. A. Levitt, I. Dorup, K. Sorensen, and I. Sullivan, “Does anthracycline administration by infusion in children affect late cardiotoxicity?” British Journal of Haematology, vol. 124, no. 4, pp. 463–468, 2004. View at Publisher · View at Google Scholar
  80. M. Gupta, P. G. Steinherz, N. K. Cheung, and L. Steinherz, “Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers,” Medical and Pediatric Oncology, vol. 40, no. 6, pp. 343–347, 2003. View at Publisher · View at Google Scholar · View at PubMed
  81. K. A. Wouters, L. C. M. Kremer, T. L. Miller, E. H. Herman, and S. E. Lipshultz, “Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies,” British Journal of Haematology, vol. 131, no. 5, pp. 561–578, 2005. View at Publisher · View at Google Scholar · View at PubMed
  82. S. E. Lipshultz, A. L. Giantris, S. R. Lipsitz et al., “Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1677–1682, 2002. View at Publisher · View at Google Scholar
  83. S. E. Lipshultz, “Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children,” Journal of Clinical Oncology, vol. 14, no. 2, pp. 328–331, 1996. View at Google Scholar
  84. C. K. Tebbi, W. B. London, D. Friedman et al., “Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 493–500, 2007. View at Publisher · View at Google Scholar · View at PubMed
  85. S. E. Lipshultz, S. R. Lipsitz, and E. J. Orav, “Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence,” Journal of Clinical Oncology, vol. 25, no. 21, p. 3179, 2007, author reply 3180. View at Publisher · View at Google Scholar · View at PubMed
  86. K. Hellmann, “Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence,” Journal of Clinical Oncology, vol. 25, no. 29, pp. 4689–4690, 2007. View at Publisher · View at Google Scholar · View at PubMed
  87. E. V. Barry, L. M. Vrooman, S. E. Dahlberg et al., “Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1106–1111, 2008. View at Publisher · View at Google Scholar · View at PubMed
  88. E. Herman, A. Knapton, J. Zhang, H. Hiraragi, and S. E. Lipshultz, “Gender is a factor that can impact the severity of doxorubicin (DXR) toxicity in spontaneously hypertensive rats (SHR),” The FASEB Journal, vol. 22, p. 719.6, 2008. View at Google Scholar
  89. R. V. Williams, L. Y. Tani, and R. E. Shaddy, “Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction,” Journal of Heart and Lung Transplantation, vol. 21, no. 8, pp. 906–909, 2002. View at Publisher · View at Google Scholar
  90. P. A. Thompson, G. L. Rosner, K. K. Matthay et al., “Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 2, pp. 243–251, 2009. View at Publisher · View at Google Scholar · View at PubMed
  91. E. G. Schuetz, K. N. Furuya, and J. D. Schuetz, “Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms,” Journal of Pharmacology and Experimental Therapeutics, vol. 275, no. 2, pp. 1011–1018, 1995. View at Google Scholar
  92. D. Belhani, L. Fanton, F. Vaillant et al., “Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine,” Cardiovascular Toxicology, vol. 9, no. 2, pp. 64–69, 2009. View at Publisher · View at Google Scholar · View at PubMed
  93. L. C. M. Kremer, E. C. van Dalen, M. Offringa, and P. A. Voûte, “Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review,” Annals of Oncology, vol. 13, no. 4, pp. 503–512, 2002. View at Publisher · View at Google Scholar
  94. J. M. LeClerc, A. L. Billett, R. D. Gelber et al., “Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01,” Journal of Clinical Oncology, vol. 20, no. 1, pp. 237–246, 2002. View at Publisher · View at Google Scholar
  95. S. E. Lipshultz, J. D. Wilkinson, S. E. Messiah, and T. L. Miller, “Clinical research directions in pediatric cardiology,” Current Opinion in Pediatrics, vol. 21, no. 5, pp. 585–593, 2009. View at Publisher · View at Google Scholar · View at PubMed
  96. C. L. Ogden, M. D. Carroll, L. R. Curtin, M. A. McDowell, C. J. Tabak, and K. M. Flegal, “Prevalence of overweight and obesity in the United States, 1999–2004,” Journal of the American Medical Association, vol. 295, no. 13, pp. 1549–1555, 2006. View at Publisher · View at Google Scholar · View at PubMed
  97. R. C. Whitaker, J. A. Wright, M. S. Pepe, K. D. Seidel, and W. H. Dietz, “Predicting obesity in young adulthood from childhood and parental obesity,” The New England Journal of Medicine, vol. 337, no. 13, pp. 869–873, 1997. View at Publisher · View at Google Scholar
  98. S. E. Messiah, K. L. Arheart, B. Luke, S. E. Lipshultz, and T. L. Miller, “Relationship between body mass index and metabolic risk factors among US 8- to 14-year olds, 1999–2002,” Journal of Pediatrics, vol. 153, no. 2, pp. 215–221, 2008. View at Publisher · View at Google Scholar · View at PubMed
  99. S. R. Daniels, M. S. Jacobson, B. W. McCrindle, R. H. Eckel, and B. M. Sanner, “American heart association childhood obesity: research summit,” Circulation, vol. 119, no. 15, pp. 2114–2123, 2009. View at Publisher · View at Google Scholar · View at PubMed
  100. L. R. Meacham, J. G. Gurney, A. C. Mertens et al., “Body mass index in long-term adult survivors of childhood cancer: a report of the childhood cancer survivor study,” Cancer, vol. 103, no. 8, pp. 1730–1739, 2005. View at Publisher · View at Google Scholar · View at PubMed
  101. P. C. Nathan, V. Jovcevska, K. K. Ness et al., “The prevalence of overweight and obesity in pediatric survivors of cancer,” Journal of Pediatrics, vol. 149, no. 4, pp. 518–525.e2, 2006. View at Publisher · View at Google Scholar · View at PubMed
  102. T. L. Miller, S. R. Lipsitz, G. Lopez-Mitnik et al., “Characteristics and determinants of adiposity in pediatric cancer survivors,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 8, pp. 2013–2022, 2010. View at Publisher · View at Google Scholar · View at PubMed
  103. B. I. Razzouk, S. R. Rose, S. Hongeng et al., “Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma,” Journal of Clinical Oncology, vol. 25, no. 10, pp. 1183–1189, 2007. View at Publisher · View at Google Scholar · View at PubMed
  104. T. M. McCambridge, D. T. Bernhardt, J. S. Brenner et al., “Active healthy living: prevention of childhood obesity through increased physical activity,” Pediatrics, vol. 117, no. 5, pp. 1834–1842, 2006. View at Publisher · View at Google Scholar · View at PubMed
  105. US Department of Health and Human Services (USDHHS), Physical Activity Guidelines Advisory Committee Report, 2008, US Department of Health and Human Services, Washington, DC, USA, 2008.
  106. K. K. Ness, W. M. Leisenring, S. Huang et al., “Predictors of inactive lifestyle among adult survivors of childhood cancer,” Cancer, vol. 115, no. 9, pp. 1984–1994, 2009. View at Publisher · View at Google Scholar · View at PubMed
  107. C. L. Cox, M. Montgomery, K. C. Oeffinger et al., “Promoting physical activity in childhood cancer survivors,” Cancer, vol. 115, no. 3, pp. 642–654, 2009. View at Publisher · View at Google Scholar · View at PubMed
  108. R. Doll and R. Peto, “Mortality in relation to smoking: 20 years' observations on male British doctors,” British Medical Journal, vol. 2, no. 6051, pp. 1525–1536, 1976. View at Google Scholar
  109. S. A. Clarke and C. Eiser, “Health behaviours in childhood cancer survivors: a systematic review,” European Journal of Cancer, vol. 43, no. 9, pp. 1373–1384, 2007. View at Publisher · View at Google Scholar · View at PubMed
  110. Centers for Disease Control and Prevention (CDC), “Cigarette smoking among adults and trends in smoking cessation—United States, 2008,” Morbidity and Mortality Weekly Report, vol. 58, pp. 1227–1232, 2009. View at Google Scholar
  111. K. Emmons, F. P. Li, J. Whitton et al., “Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the Childhood Cancer Survivor Study,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1608–1616, 2002. View at Publisher · View at Google Scholar
  112. K. M. Emmons, E. Puleo, A. Mertens, E. R. Gritz, L. Diller, and F. P. Li, “Long-term smoking cessation outcomes among childhood cancer survivors in the partnership for health study,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 52–60, 2009. View at Publisher · View at Google Scholar · View at PubMed
  113. C. C. Cowie, K. F. Rust, E. S. Ford et al., “Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005-2006,” Diabetes Care, vol. 32, no. 2, pp. 287–294, 2009. View at Publisher · View at Google Scholar · View at PubMed
  114. L. R. Meacham, C. A. Sklar, S. Li et al., “Diabetes mellitus in long-term survivors of childhood cancer—increased risk associated with radiation therapy: a report for the childhood cancer survivor study,” Archives of Internal Medicine, vol. 169, no. 15, pp. 1381–1388, 2009. View at Publisher · View at Google Scholar · View at PubMed
  115. K. A. Neville, R. J. Cohn, K. S. Steinbeck, K. Johnston, and J. L. Walker, “Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4401–4407, 2006. View at Publisher · View at Google Scholar · View at PubMed
  116. B. M. Egan, Y. Zhao, and R. N. Axon, “US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008,” Journal of the American Medical Association, vol. 303, no. 20, pp. 2043–2050, 2010. View at Publisher · View at Google Scholar · View at PubMed
  117. E. H. Herman, A. N. El-Hage, V. J. Ferrans, and B. Ardalan, “Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats,” Toxicology and Applied Pharmacology, vol. 78, no. 2, pp. 202–214, 1985. View at Google Scholar
  118. D. L. Hershman, R. B. McBride, A. Eisenberger, Y. T. Wei, V. R. Grann, and J. S. Jacobson, “Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3159–3165, 2008. View at Publisher · View at Google Scholar · View at PubMed